Hepion Pharmaceuticals announces USAN selection of


[ad_1]

EDISON, NJ, Jan. 6, 2022 (GLOBE NEWSWIRE) – Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical-stage biopharmaceutical company focused on the development of artificial intelligence (“AI”) -based therapeutic drugs for the treatment of alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that the United States Adopted Names Board (“USAN”) has adopted the common name “rencofilstat” for the main The Company’s drug candidate, CRV431.

The USAN Council (sponsored by the American Medical Association, United States Pharmacopeia, and American Pharmacists Association) works closely with the International Nonproprietary Name Program of the World Health Organization and various national nomenclature groups to achieve to the global standardization and unification of medicines. nomenclature and related rules to ensure that drug information is communicated accurately and unambiguously.

Going forward, Hepion will use the name “rencofilstat” in future publications and public statements, at conferences and other forums, as the Company continues to advance the clinical development of the drug.

About Hepion Pharmaceuticals

The Company’s main drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in the clinical development phase for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease – from trigger events to the end stage of the disease. Rencofilstat has been shown to reduce hepatic fibrosis and tumor burden of hepatocellular carcinoma in experimental models of NASH, and has demonstrated antiviral activities against HBV, HCV and HDV through several mechanisms, in studies non-clinical. In November 2021, the United States Food and Drug Administration (“FDA”) granted rencofilstat Fast Track designation for the treatment of NASH. This was quickly followed in December 2021 by the FDA acceptance of Hepion’s Investigational New Drug Application (IND) for rencofilstat for the treatment of hepatocellular carcinoma (HCC).

Hepion has created a proprietary AI platform, called AI-POWR â„¢, which stands for AArtificial intelligence – Pprecision medicine; ohmicros (including genomics, proteomics, metabolomics, transcriptomics and lipidomics); Waccess to the global database; and Rresponse and clinical results. Hepion intends to use AI-POWR â„¢ to help identify NASH patients who will respond best to encoflistat, potentially shortening development times and increasing the delta between the placebo and treatment groups. In addition to using AI-POWR â„¢ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for encoflistat to expand the footprint of society in the therapeutic space of cyclophilin inhibition.

Forward-looking statements

Certain statements contained in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate”, “believe”, “anticipate”, “ estimated ”and“ intention ”, among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by these forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue to operate; our need for additional financing; uncertainties in patent protection and litigation; the risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties regarding long and expensive clinical trials, the fact that the results of previous studies and trials may not be predictive of the results of future trials; uncertainties regarding reimbursement from the government or a third party payer; limited sales and marketing efforts and reliance on third parties; and risks associated with failure to obtain FDA clearances or approvals and failure to comply with FDA regulations. As with any drug candidate under development, there are significant risks in the development, regulatory approval and commercialization of new products. There is no guarantee that future clinical trials discussed in this press release will be completed or successful, or that a product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake to update or revise any forward-looking statement. Investors should read the risk factors set out in Hepion Pharmaceuticals Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission.

For more information, please contact:

Stephen kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
[email protected]

[ad_2]

Comments are closed.